An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Balixafortide (Primary) ; Eribulin
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms FORTRESS
- Sponsors Polyphor
- 19 Jun 2019 According to an Polyphor media release, the company announced the enrollment of the first patient in this trial.
- 26 May 2019 Status changed from not yet recruiting to recruiting.
- 13 May 2019 Planned initiation date changed from 1 Mar 2019 to 1 May 2019.